Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 3

1.

Deficient TP53 expression, function, and cisplatin sensitivity are restored by quinacrine in head and neck cancer.

Friedman J, Nottingham L, Duggal P, Pernas FG, Yan B, Yang XP, Chen Z, Van Waes C.

Clin Cancer Res. 2007 Nov 15;13(22 Pt 1):6568-78.

2.

p53-based therapeutics for head and neck squamous cell carcinoma.

Tassone P, Old M, Teknos TN, Pan Q.

Oral Oncol. 2013 Aug;49(8):733-7. doi: 10.1016/j.oraloncology.2013.03.447. Epub 2013 Apr 25. Review.

3.

A Candidate Cell-Selective Anticancer Agent.

Lewis TA, de Waal L, Youngsaye W, Gechijian L, Hickey M, Faloon P, Mikse O, Dandapani S, Wong K, Tolliday N, Munoz B, Palmer M, Greulich H, Meyerson ML, Schreiber SL.

Probe Reports from the NIH Molecular Libraries Program [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2010-.
2013 Dec 12 [updated 2014 Sep 18].

Supplemental Content

Support Center